Semaxinib is a quinolone derivative with potential antineoplastic activity. Semaxinib reversibly inhibits ATP binding to the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2), which may inhibit VEGF-stimulated endothelial cell migration and proliferation and reduce the tumor microvasculature. This agent also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells. Source summary: Semaxinib is a potent tyrosine kinase inhibitor used in the study of signaling pathways and cancer research. Enhance your research; inquire now for availability!
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | VEGFR
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye